Genentech Inc, a US biotechnology research company, plans to found a research joint venture with the Taiwanese government in Hsinchu to develop AIDS treatments headed by Taiwanese-American researcher David Ho (何大一), Chinese-language news-papers said yesterday.
Ho has reportedly agreed to serve as chairman of the planned joint-venture -- to be known as TaiMed -- which is to be set up in Hsinchu Biochemical Science Park (新竹生醫科學園區), reports quoted Liang Chi-ming (梁啟銘), director of the Office of Public Affairs at the Academia Sinica, as saying.
Academia Sinica is the nation's top research institute.
South San Francisco-based Genentech will transfer its CD4 antibody technology to TaiMed, the United Daily News said, citing Liang.
CD4, which exists on the membrane of T cells, is a primary receptor used by HIV-1 to gain entry into host T cells, which plays an essential role in cell-mediated immunity and targets of HIV infection. If developed successfully, the CD4 antibody will block CD4 from destroying the immune system.
Funding for the joint-venture should reach NT$3 billion (US$90.5 million) for the first three years, with the Cabinet's Development Fund investing in as much as 45 percent of that, the paper quoted Liang as saying. The rest of the funds will come from private enterprises and venture capital, the paper said.
The China Times carried a similar report yesterday, citing Council for Economic Planning and Development chairwoman Ho Mei-yueh (
But the government investment will not exceed 45 percent, or the company would become state-run, Ho said in the report.
Liang said that the project was initiated by Academia Sinica President Wong Chi-huey (翁啟惠), who hopes to establish a research firm to attract overseas Taiwanese biotech researchers back to the nation.
Ho, well-known for pioneering the use of protease inhibitors in treating HIV-infected patients with his team, will be hired as a researcher by the Academia Sinica and then assume the chairmanship of TaiMed, the reports said, quoting Liang.
The CD4 treatment, along with Ho's cocktail drug for curbing AIDS in its early period, will be the focus at TaiMed, Liang said.
If the new drug is successful, TaiMed could earn royalties from drug manufacturers and obtain sales right in East Asia, he said.
The legislature passed the Biotech and New Pharmaceutical Development Act (生技新藥產業發展條例) last Friday, which allows government researchers to transfer their knowledge to private companies developing new drugs.
DIVIDED VIEWS: Although the Fed agreed on holding rates steady, some officials see no rate cuts for this year, while 10 policymakers foresee two or more cuts There are a lot of unknowns about the outlook for the economy and interest rates, but US Federal Reserve Chair Jerome Powell signaled at least one thing seems certain: Higher prices are coming. Fed policymakers voted unanimously to hold interest rates steady at a range of 4.25 percent to 4.50 percent for a fourth straight meeting on Wednesday, as they await clarity on whether tariffs would leave a one-time or more lasting mark on inflation. Powell said it is still unclear how much of the bill would fall on the shoulders of consumers, but he expects to learn more about tariffs
NOT JUSTIFIED: The bank’s governor said there would only be a rate cut if inflation falls below 1.5% and economic conditions deteriorate, which have not been detected The central bank yesterday kept its key interest rates unchanged for a fifth consecutive quarter, aligning with market expectations, while slightly lowering its inflation outlook amid signs of cooling price pressures. The move came after the US Federal Reserve held rates steady overnight, despite pressure from US President Donald Trump to cut borrowing costs. Central bank board members unanimously voted to maintain the discount rate at 2 percent, the secured loan rate at 2.375 percent and the overnight lending rate at 4.25 percent. “We consider the policy decision appropriate, although it suggests tightening leaning after factoring in slackening inflation and stable GDP growth,”
Meta Platforms Inc offered US$100 million bonuses to OpenAI employees in an unsuccessful bid to poach the ChatGPT maker’s talent and strengthen its own generative artificial intelligence (AI) teams, OpenAI CEO Sam Altman has said. Facebook’s parent company — a competitor of OpenAI — also offered “giant” annual salaries exceeding US$100 million to OpenAI staffers, Altman said in an interview on the Uncapped with Jack Altman podcast released on Tuesday. “It is crazy,” Sam Altman told his brother Jack in the interview. “I’m really happy that at least so far none of our best people have decided to take them
As they zigzagged from one machine to another in the searing African sun, the workers were covered in black soot. However, the charcoal they were making is known as “green,” and backers hope it can save impoverished Chad from rampant deforestation. Chad, a vast, landlocked country of 19 million people perched at the crossroads of north and central Africa, is steadily turning to desert. It has lost more than 90 percent of its forest cover since the 1970s, hit by climate change and overexploitation of trees for household uses such as cooking, officials say. “Green charcoal” aims to protect what
RSS